1 8 9 a r t i c l e s Most mammalian genes use alternative splicing (AS) to express multiple mRNA isoforms; thus, AS is a major contributor to proteome complexity. The serine/arginine-rich (SR) protein SRSF6 (SRp55) belongs to a family of highly conserved RNA-binding splicing-factor proteins 1,2 , with one or two RNA-recognition motifs and a C-terminal arginine/serine-rich (RS) domain 3 . The RNA-recognition motifs mediate binding to specific exonic-splicing-enhancer motifs, whereas the RS domain engages in protein-protein interactions modulated by serine phosphorylation and dephosphorylation.
a r t i c l e s Using live imaging of shaved, Dox-treated animals, we analyzed GFP induction for 21 d (Fig. 1b) . We observed a gradual increase in GFP expression in the skin and severe epithelial hyperplasia in the skin and small intestine ( Fig. 1c-e and Supplementary Table 1a ). Hyperplasia is the first stage of cancer development.
The initial lesion was characterized by an abnormal increase in keratinocyte number in the interfollicular epithelium and infundibulum and distal isthmus of the hair follicles. There was mild to moderate achanthosis, hypergranulosis and hyperkeratosis ( Supplementary Fig. 2) . The severity of the hyperplasia increased during the Dox-induction time course. In the more severe lesions, the progression of morphologic differentiation generally followed the normal pattern but was severely hyperplastic and mildly to moderately dysplastic, with thickening and loss of organization of the stratum spinosum, irregularities in the stratum granulosum and severe parakeratotic hyperkeratosis ( Supplementary Fig. 2e,f) . The epithelium of the hair follicles was hyperplastic, and abnormal hair formation was often present. The adnexa were also hyperplastic with squamous metaplasia. The lesions were clearly demarcated ( Supplementary Fig. 2a,b) . In advanced lesions, other abnormalities included intraepidermal microabscesses, dyskeratotic keratinocytes, spongiosis, apoptotic basal cells (Civatte bodies) and increased apoptotic bodies (Supplementary Fig. 3 ). There were areas of epidermal thickening, with an approximately eight-fold increase in thickness compared to that of normal skin (P < 0.0001) ( Fig. 1d) . Depilation by plucking caused a more severe phenotype (Supplementary Fig. 4) .
In the most severe cases, the skin was remarkably thickened, with thick verrucose proliferative lesions adjacent to papules with severe epidermal hyperplasia, especially in the mice with plucked hair. In the severe verrucose lesions, the parakeratotic hyperkeratotic stratum corneum was up to 1 mm thick, and it surrounded and trapped the hair shafts. The parakeratosis was often severe, with retention of large nuclear fragments and many apoptotic bodies. The surface was covered with crusts. The underlying epidermis was markedly thickened and formed folds reminiscent of papillary development. The epidermis was irregular, with marked variation in cellular differentiation and orientation. The granular cell layer was prominent, and often thickened, and it displayed variation in keratohyalin granules. There was severe dyskeratosis as well as many apoptotic bodies and mitoses above the basal layer. Keratin pearls were present in the epidermis, as a result of trapping in misoriented interpapillary areas (Supplementary Fig. 4) .
In the middle of the most severely affected areas, the hair bulb, stem and glands of the follicles were often absent. This loss of intact follicles is typical of hyperplastic epidermis and wound healing.
In the small intestine, we observed segmental areas of severe cryptepithelial hyperplasia, with blunting of the villi. The lower penetrance of intestinal hyperplasia (five of nine mice) compared with skin (eight of eight mice) may be due to the intestinal lesions being segmental and occurring in random portions of the intestine that we did not always sample. Control skin from double-transgenic animals in the absence of Dox, or from Dox-treated wild-type or R26-rtTA mice, showed no signs of hyperplasia ( Supplementary Table 1a ). We conclude that SRSF6 overexpression in mouse skin and small intestine induces hyperplasia.
To further characterize SRSF6-expressing cells, we analyzed the epidermis for colocalization with skin differentiation markers in mild to moderate lesions. We found that ectopic SRSF6 expression was strongly associated with keratin 5 and keratin 14 ( Fig. 2a,c) . These markers of proliferating basal cells were expressed throughout the epidermis, results suggesting a failure of the cells to differentiate and mature. We also detected a high level of proliferation, measured by antigen Ki-67 and also by keratin 6, which is strongly expressed in activated keratinocytes and is normally observed during epidermal injury 16 (Fig. 2a) . In contrast, epithelial hyperplasia coincided with reduced levels of loricrin ( Fig. 2c) npg a r t i c l e s early in the hyperplastic epidermis. We infer that enforced expression of SRSF6 maintains cells in an aberrant proliferating state, thus suppressing the normal epithelial differentiation program.
SRSF6-driven skin phenotype is cell autonomous
Immunofluorescence microscopy showed that ectopic SRSF6 (T7-tagged) protein was exclusively expressed in the hyperplastic epithelium and hair follicles ( Fig. 2a ). There was no transgene expression in the stroma adjacent to the affected epithelium. We tested whether skin hyperplasia was cell autonomous or depended, for example, on cells originating in the hematopoietic system in the spleen or bone marrow, which showed sporadic SRSF6 expression ( Supplementary Fig. 1c ). We grafted allogenic transplants made from double-transgenic or control skin onto recipient nude mice. Upon Dox treatment, only mice with double-transgenic transplants developed hyperplasia ( Supplementary Table 1b ), results indicating that skin hyperplasia occurs cell autonomously upon induction of SRSF6 expression within the epithelium (Fig. 2b) .
SRSF6 induces a wound-healing expression signature
To identify genes affected by SRSF6 overexpression, we used genome-wide expression microarrays, which yielded sets of differentially expressed genes in epidermal hyperplasia: 989 genes were upregulated, and 1,201 were downregulated by more than two-fold (Supplementary Table 2 ). Clustering analysis clearly separated the skin samples from the Dox-treated versus the normal mice, thus indicating inherent changes in the transcriptional profiles ( Fig. 2d) . Gene Ontology analysis of the upregulated genes showed significant enrichment in terms associated with the mitotic cell cycle (P < 2.6 × 10 −23 ), response to wounding (P < 8.3 × 10 −12 ), epidermal differentiation (P < 4.7 × 10 −7 ) and cell proliferation (P < 1.3 × 10 −3 ) (Supplementary Table 2 ).
RT-PCR validation ( Supplementary Fig. 5 and primer sequence information in Supplementary Note 1) confirmed the strong induction of keratin 6 (154-fold) and keratin 16 (13-fold)-two markers of tissue injury 16 . Similarly, many proinflammatory cytokines important for wound healing were upregulated, including Tnf (6-fold), Il1b (24-fold), Cxcl2 (97-fold) and Ccl3 (43-fold). Importantly, tenascin C (Tnc), an extracellular-matrix protein commonly expressed at sites of epithelial-mesenchymal transition in embryos 17 and at sites of inflammation 18 , increased six-fold.
A hallmark of wound healing is collagen deposition at injury sites and adjacent stroma during the proliferative phase 13 . Despite the lack of ectopic SRSF6 expression in stroma, we detected increased levels of thick collagen fibrils and total collagen by quantitative polarized-light microscopy of Picrosirius red-stained tissues (P < 0.0001) ( Fig. 2e) . Collectively, these results indicate that epidermal SRSF6 overexpression activates genes directly involved in the wound-healing response and results in excessive collagen deposition.
A new role of SRSF6 in wound healing
We next searched for conditions that modulate the observed phenotype. Intriguingly, simply shaving the hair greatly enhanced SRSF6-induced epidermal hyperplasia ( Fig. 3a) . This implicates stem-cell activation in the phenotype because depilation or injury can activate stem cells within the hair-follicle bulge 19, 20 . Supporting this interpretation, hair-follicle areas of unshaved skin occasionally contained a few GFP-positive cells upon Dox induction (data not shown), and a few focal areas of local hyperplasia appeared without shaving ( Fig. 3a) . Similarly, full-thickness longitudinal incisions to the tails of transgenic animals resulted in progressive development of epidermal hyperplasia proximal to the wound, within 1 week after Dox induction; in contrast, no GFP-positive epidermal cells were present in regions distal to the wound (Fig. 3b) . Cross-sections confirmed that wound-induced hyperplasia was closely restricted to the wound site and surrounding tissue. Consistently with this observation, epidermal thickness increased approximately three-fold at sites distal to the wound compared to control epidermis ( Fig. 3c) . Epidermal thickness at wound-proximal sites likewise increased significantly ( Fig. 3c) . Although SRSF6 had no effect on the wound-closure rate, it resulted in significantly wider wounds (data not shown).
We next investigated whether SRSF6 is normally involved in wound healing. We extracted protein from wounded tail skin or shaved back skin of double-transgenic mice for immunoblot analysis. npg a r t i c l e s Indeed, 1 week after wounding, endogenous SRSF6 increased ( Fig. 3d) . Moreover, wounding was required to maximally elevate total SRSF6 protein in the context of Dox induction ( Fig. 3d ). We observed a very similar pattern in shaved skin: shaving increased endogenous SRSF6 protein and was required to maximally increase total SRSF6 upon Dox induction ( Fig. 3d) . These results suggest that SRSF6 is important for normal wound healing; however, under SRSF6 overexpression conditions, the normal tissue-repair process is misregulated, thus resulting in skin hyperplasia, probably owing to aberrant stem-cell activation.
To further investigate skin stem-cell dynamics during SRSF6induced skin hyperplasia, we analyzed the expression of the hair-follicle stem-cell markers Krt15, Lgr4, Lgr5 and Lgr6 (ref. 21) . Interestingly, quantitative PCR (qPCR) analysis showed specific depletion of Lgr6, which marks an upper-hair-follicle stem-cell subtype, in contrast to the lower-hair-follicle LGR5+ stem cells, which did not change significantly in skin samples with SRSF6-induced hyperplasia (Fig. 3e) . The hair-follicle-bulge marker Krt15 was also reduced upon hyperplasia, as expected. In certain situations, broad stem-cell activation can lead to stem-cell depletion, for example, upon ectopic c-myc overexpression in mouse skin 22 . These results further support the notion that hairfollicle stem cells are directly activated and may be required for initiating SRSF6-induced epidermal hyperplasia.
To test whether SRSF6 can affect stem-cell self-renewal or differentiation in vitro, we purified and cultured primary keratinocytes from double-transgenic or control mice and plated them to determine the effect of SRSF6 overexpression on the number of colonies formed, a reflection of the original number of stem cells seeded 23 . After 10 d of culture, we did not detect any colonies from Dox-induced SRSF6transgenic keratinocytes ( Fig. 3f) , results consistent with specific stem-cell depletion upon SRSF6 overexpression. We also showed by qPCR and immunoblotting that induction of SRSF6 promotes differentiation of cultured primary keratinocytes ( Supplementary Fig. 6 ). Importantly, markers of differentiation were strongly induced (Krt1, +743-fold; Flg, +32-fold), whereas markers of undifferentiated cells changed only slightly (Krt5, +3-fold; Krt14, +2-fold). These results suggest that SRSF6 can impair stem-cell renewal and/or promote differentiation of epidermal stem cells, both in vivo and in vitro. In vivo, SRSF6 overexpression in skin prevents basal keratinocytes from undergoing complete terminal differentiation.
SRSF6 promotes cassette-exon inclusion in hyperplastic skin
To investigate the impact of SRSF6 overexpression on AS, we analyzed the raw microarray expression data by using the exon splicing-index method 24 . Pairwise comparisons identified common AS events (ASEs), yielding a set of 154 alternatively spliced exons from 139 unique genes ( Fig. 4a) . We observed almost exclusively increased exon inclusion (153 of 154 events) upon SRSF6 induction in skin, results illustrating SRSF6's inherent function as a splicing activator ( Fig. 4a and Supplementary Table 2) . These changes were not attributable to gene-expression changes because the latter did not correlate with exon splicing-index scores.
SR proteins, including SRSF6, bind to degenerate ESEs in pre-mRNA, from where they activate splicing 25 . To further address the mechanisms of SRSF6-induced hyperplasia, we performed bindingmotif prediction by using MEME 26 internal exons that we used in combination with a random set of cassette exons (as background reference) to predict de novo a consensus SRSF6 motif. We identified a 9-mer motif with an e value of 2.5 × 10 8 ('SRSF6 in vivo motif '). This motif differed only slightly from the 6-mer motif found by in vitro functional systematic evolution of ligands by exponential enrichment (SELEX) 27 , results consistent with its presumed functionality in vivo ( Supplementary  Fig. 7) . Furthermore, the SRSF6 motif did not resemble the SELEX motifs of other SR proteins 27 . Next, we validated the AS changes by using RT-PCR with an independent set of skin samples, either SRSF6 overexpressing or controls (n = 10). We successfully validated 16 of 22 cassette exons, for an overall success rate of 73% (Supplementary Fig. 4a-c and Supplementary Tables 2 and 3a) . Prominent validated examples include pyruvate kinase M (Pkm) exon 9 (−3.2); tenascin C (Tnc) exons 10 (+3.0), 11 (+2.6), 12 (+3.2), 13 (+4.5) and 15 (+3.8); and transcription factor Elk4 exon 2 (+1.7) ( Fig. 4b-d ). hnRNPA1 and hnRNPA2, PTB and SRSF3 contribute to regulating human PKM AS [28] [29] [30] , and our present data also implicate SRSF6 in regulating mouse Pkm AS. The extracellular-matrix protein TNC is a particularly intriguing new target of SRSF6 because it is specifically expressed at sites of tissue injury and inflammation and in chronic wounds and cancer 18, 31 . Alternatively spliced exons of Tnc scored among the highest changes in our analysis, results consistent with this gene's potential role as a functionally relevant target of SRSF6. npg
Tnc is a target gene of SRSF6
To determine how SRSF6 controls Tnc AS, we searched for putative SRSF6 motifs within exons at or near the alternatively spliced region of Tnc, by using SFmap 32 . The predicted SRSF6 motif was enriched in the highly conserved alternative exons of Tnc, compared to the flanking constitutive exons, even though the former exons are smaller ( Fig. 5a and Supplementary Table 3b ). Furthermore, the presence of SRSF6 motifs in the alternative exons inversely correlated with the strength of their 5′ splice sites ( Fig. 5a and Supplementary Table 3b ), thus suggesting that SRSF6 binding to these exonic-splicing-enhancer motifs is required to promote more efficient alternative-exon inclusion.
To directly measure whether SRSF6 binds alternatively spliced Tnc mRNA, we transiently overexpressed T7-tagged SRSF6 cDNA or empty-vector control in NIH-3T3 cells. After UV-irradiating the cells, we isolated cross-linked adducts by immunoprecipitation with immobilized anti-T7-tag antibody. We then purified the bound mRNA and analyzed it by RT-PCR, using primers specific for either Tnc exons 9 and 10 or exons 15 and 16. In both cases, SRSF6 specifically bound to alternatively spliced Tnc mRNA, compared to empty-vector control (Fig. 5b) . As expected, there was no product when we omitted reverse transcriptase.
To investigate where along Tnc mRNA SRSF6 binds in cells, we repeated the experiment, but with micrococcal nuclease digestion before immunoprecipitation. We then measured by qPCR the relative RNA enrichment for each alternative Tnc exon (10 to 15) ( Fig. 5c ). SRSF6 associated with alternative exons 10 to 14 but not with exon 15. However, the latter lack of association could be due to weak nuclease protection or inefficient cross-linking because exon 15 has six SRSF6 motifs. To test the functionality of the predicted SRSF6-binding sites, we performed RNA pulldowns with three 21-mer oligonucleotides comprising nucleotide positions 23-42 of mouse Tnc exons: one from exon 12; another with a mutated binding site; and the last with two SRSF6-binding sites from exon 15. Intriguingly, endogenous SRSF6 strongly bound mouse wild-type E15 and E12, but not mutant E12, under splicing conditions in nuclear extract from HeLa cells (Fig. 5d) .
We then asked whether SRSF6 knockdown affects Tnc AS. We transiently transfected NIH-3T3 cells with short interfering RNA (siRNA) against luciferase or Srsf6. We quantitated Tnc AS as the ratio between long isoforms and total Tnc, using specific qPCR primers for exons 8 and 9 (total Tnc) and 15 and 16 (long isoforms). Srsf6 knockdown resulted in downregulation of the long Tnc isoforms, compared to total Tnc (Fig. 5e and target-sequence information in Supplementary Note 2). We confirmed this result by RT-PCR. Importantly, the short Tnc isoform, with exons 10-15 deleted (∆E10-15), was unaffected by Srsf6 knockdown (Supplementary Fig. 7d ). This is consistent with the Tnc splicing changes observed upon SRSF6 overexpression, in that the ∆E10-15 isoform was likewise unaffected (Fig. 4c) . We confirmed the decrease in the long TNC protein isoform by immunoblotting with isoform-specific antibody (Fig. 5e) .
Tenascin-C AS correlates with phenotypic severity
To study the spatial and temporal effects of SRSF6 expression on Tnc splicing, and its effects on skin pathology, we performed a time-course experiment, feeding mice Dox for 0-7 d. We observed a delay in the Tnc switch toward the long isoform after SRSF6 induction (Fig. 6a) . This fits with the expectation that SRSF6 expression needs to reach a certain level before it can affect splicing of its targets. , which was undetectable in normal uninduced skin (Fig. 6b) . Moreover, histopathology of induced skin tissues confirmed that the Tnc splicing switch was associated with induction of hyperplasia ( Fig. 6c) . However, the timing and duration of SRSF6 induction was critical. During normal tissue wound healing, the onset of keratinocyte proliferation starts ~1-2 d after injury 12, 13 . Here, we observed that if SRSF6 was persistently expressed on days 0-7 after injury, severe skin hyperplasia was induced. In contrast, if SRSF6-enforced expression was stopped by removal of Dox on day 2 after injury, skin hyperplasia was no longer present on day 7 (Fig. 6c) .
Hence, sustained SRSF6 expression is required during the proliferative phase of keratinocytes to drive hyperplasia. To further explore the role of SRSF6 and its specific target isoform, Tnc-FL, in wound healing, we used in vitro assays. Consistently with its role in hyperplasia, SRSF6 significantly increased cell migration when overexpressed in NIH-3T3 cells (Fig. 6d) . Importantly, this stimulatory effect of SRSF6 was suppressed by shRNA knockdown of Tnc to result in strong downregulation of the Tnc-FL isoform (Fig. 6e) . In addition, we tested whether SRSF6 controls cell migration through splicing regulation of TNC in A2058 human melanoma cells, which express high levels of TNC-FL 33 . SRSF6 knockdown by two independent inducible shRNAs resulted in reduced levels of TNC-FL and decreased cell migration. We obtained similar results by inducible shRNA knockdown of TNC-FL ( Fig. 6f and Supplementary Fig. 8) . These findings are consistent with a previous report showing that TNC promotes cell migration mainly through its long isoform (TNC-FL), whereas the short isoform lacks this ability 34 . We conclude, on the basis of these data, that regulation of TNC AS by SRSF6 is cell-type independent and has a causal role in promoting wound healing in vitro.
Overexpression of both SRSF6 and TNC-FL in skin cancer
SRSF1 is a proto-oncogene that can transform rodent fibroblasts and mammary epithelial cells 6, 7 . Because SRSF1 and SRSF6 are closely related orthologs, we investigated whether SRSF6 is likewise an oncogenic splicing factor. We transduced mouse embryonic fibroblasts (MEFs) (p53 −/− , c-myc + ) with either SRSF6 cDNA or empty vector, injected them subcutaneously into nude mice and allowed tumors to develop ( Supplementary Table 4 ). SRSF6 strongly promoted sarcomagenesis after only 4 weeks (Fig. 7a) .
Considering the skin hyperplasia caused by SRSF6 overexpression, and its overexpression in different human cancers 6 , we measured SRSF6 levels in skin cancers in particular. To assess SRSF6 protein expression, we stained tissue microarrays, comprising multiple tumor specimens, with a monoclonal antibody. Remarkably, we found significantly elevated levels of SRSF6 protein in basal-cell carcinomas (BCC; n = 20, P < 0.0001), squamous-cell carcinomas (SCC; n = 18, P < 0.0001) and malignant melanomas (n = 27, P = 0.01) (Fig. 7b) . These data are consistent with SRSF6's potential role in human skin cancer and with SRSF6 being a proto-oncogene. We also stained serial tissue microarrays containing 92 human melanoma specimens with antibodies to either SRSF6 or TNC-FL. SRSF6 and TNC-FL proteinisoform levels were strongly correlated (66.3% of the cases, P = 0.0002) ( Fig. 7c,d) . High SRSF6 levels were only infrequently linked to low levels of TNC-FL protein (5.4%). These results suggest that in addition to its role in normal skin, SRSF6 controls TNC-FL protein levels in the context of skin cancer. However, our data suggest that additional factors also regulate TNC-FL levels because some tumors have high TNC-FL levels without SRFS6 overexpression.
In summary, SRSF6 regulates multiple AS events in vivo. When its normal level is perturbed-as it is in many cancers-it gives rise to skin hyperplasia, and we identified tenascin C as one of its prominent target genes, whose AS pattern is strongly associated with skin cancer. These observations reinforce the importance of AS regulation for cancer progression. Furthermore, our study identifies SRSF6 and/or the genes it controls as potential targets for therapeutic intervention in skin cancer.
DISCUSSION
We demonstrated that overexpression of the SR protein SRSF6 causes skin hyperplasia in mice by deregulating tissue homeostasis. We also found statistically significant overexpression of SRSF6 in human BCC, SCC and malignant melanoma. Moreover, we showed that enforced expression of SRSF6 is sufficient to transform p53-null, myc-expressing primary fibroblasts in allograft assays. The latter observation resembles earlier findings in other contexts for the SRSF6 paralogs SRSF1 (refs. 6,7) and SRSF3 (ref. 8) , both of which are protooncogenes, thus extending the evidence for oncogenic SR proteins.
Our results suggest that SRSF6 has a role in normal wound healing that is potentially related to its role in cancer. Indeed, we found that endogenous SRSF6 is elevated upon skin injury. We hypothesize that under physiological conditions reminiscent of tissue injury, SRSF6 is induced to regulate certain target effector genes at the level of AS, thus allowing an efficient and appropriate wound-healing response. Our data suggest a possible mechanism for how excessive SRSF6 expression might instead result in abnormal hyperplasia (Fig. 8) . nature structural & molecular biology VOLUME 21 NUMBER 2 FEBRUARY 2014 1 9 5 a r t i c l e s npg a r t i c l e s Normally, keratinocytes respond to injury by becoming activated, a state characterized by strong expression of Krt6 and Krt16. Activated keratinocytes also release the cytokine interleukin-1-the first signal upon wounding-to further increase keratinocyte activation and alert surrounding tissues 35 . Indeed, using microarray expression analysis of skin tissues, we found that SRSF6 induction resulted in strong upregulation of Krt6, Krt16, Il1b and many other woundhealing markers.
One of the main pathological features of SRSF6-induced hyperplasia is the dependence on somatic stem-cell activation to achieve the full phenotype. Thus, the onset of hyperplasia was strongly enhanced by either hair shaving or tissue wounding, conditions in which skin stem cells are specifically activated 21, 36 . We did observe focal hyperplastic lesions in unshaved mice, which probably reflect scratching or hair pulling.
Intriguingly, skin hyperplasia was associated with depletion of LGR6+ cells. These skin stem cells reside in the upper part of the hair follicle and participate in wound healing upon tissue injury 21 . We demonstrated that the effects of SRSF6 are cell autonomous and therefore are consistent with a leading role of stem-cell activation because transplanted skin grafts recapitulated the phenotype upon shaving and Dox treatment. Supporting evidence with cultured primary keratinocytes showed that SRSF6 expression repressed colony-formation capacity and promoted differentiation. These findings suggest a role of SRSF6 in repressing self-renewal signals and promoting differentiation. The reasons why SRSF6 promotes proliferation and the initial steps of differentiation but represses terminal differentiation remain unknown. Overexpression of SRSF6 may maintain keratinocytes in an abnormal activation state that otherwise would be temporary during normal tissue repair. Additional studies are needed to understand this phenomenon in detail.
Strikingly, for the genes that showed changes in AS in skin upon SRSF6 overexpression, nearly all the changes consisted of increased exon inclusion, thus confirming SRSF6's role as a strong splicing activator. A consensus 9-mer binding motif was present in all 84 internal alternative exons. Moreover, we demonstrated specific binding of SRSF6 to alternatively spliced Tnc exons with the binding motifs.
Due to the complex nature of AS regulation in vivo, and the global effects of individual SR proteins, such as SRSF6, it is difficult to demonstrate a direct causal relationship between expression of individual isoforms and the observed hyperplastic phenotype. Intriguingly, however, some of the isoforms promoted by SRSF6 represent the reappearance of an embryonic splicing pattern. In particular, the M2 isoform of Pkm is specifically expressed in embryonic tissues and in cancers 37 . Similarly, the long Tnc isoform (+E10-15 or +E10-18 (human)) is expressed in neuronal stem cells and embryonic tissue 38 and in many types of invasive and metastatic cancer 34, [39] [40] [41] [42] [43] . In breast cancer cells, the two long TNC isoforms, +E10-15 and ∆E14, drive increased cell migration and proliferation in vitro 34 . Also, the plasma level of the long TNC isoform is a putative predictive marker for metastatic colon cancer 44, 45 . We showed here that SRSF6 specifically promotes AS of the +E10-15 and ∆E14 Tnc isoforms, without changing the levels of the constitutive ∆E10-15 isoform, even though we observed an increase in total Tnc expression upon induction of hyperplasia.
Consistently with SRSF6 being a likely regulator of Tnc AS, we observed a direct relationship between the magnitude of the change in Tnc AS, the SRSF6 expression level and the extent of hyperplasia over time. Moreover, when SRSF6 induction was withdrawn, Tnc AS reverted, as did the hyperplastic phenotype. The relevance of SRSF6 as a regulator of Tnc AS was not limited to cell lines and mouse skin but was also evident in human melanomas, which showed a strong correlation between SRSF6 and TNC-FL protein levels. We have thus discovered a notable connection between clinically proven, important isoforms of Tnc and a member of the SR-protein family of splicing regulators.
Future work will be required to confirm that Tnc AS has a key role in driving the development and maintenance of skin hyperplasia and possibly other related pathological conditions. It will also be important to understand how SRSF6 is naturally regulated during wound healing and whether other splicing factors contribute to these processes as well.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. All raw microarray data files are available from the Gene Expression Omnibus database under accession code GSE52458.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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M.A.J. and A.R.K. designed the study and wrote the paper. M.A.J. and J.E.W. carried out the experiments and analyzed the data. All authors read the manuscript. Figure 8 Model for the dynamic role of SRSF6 in skin hyperplasia and wound healing. Bottom (blue), normal tissue homeostasis in skin. Top (red), during tissue injury, expression of SRSF6 is induced (and perhaps required) to regulate or promote unknown processes that are part of normal wound healing, acting through AS of target genes, for example, Tnc and others. When SRSF6 expression is elevated, skin stem cells are aberrantly activated upon stimulation (by shaving or wounding), thus causing skin hyperplasia. SRSF6 probably suppresses stem-cell selfrenewal signals and/or stimulates stem-cell differentiation to keratinocyte progenitors that are maintained in a proliferating state. Aberrant levels of the SRSF6 splicing target Tnc-FL protein isoform may have a disruptive role for maintenance of the stem-cell niche microenvironment. a r t i c l e s
